Boe 1989.

Methods	Setting: multicentre study Sweden, hospital outpatient clinic Randomisation: yes, using 4x4 Williams square Allocation concealment: unclear Masking: double blind Design: crossover, no washout Length of intervention period: 4 weeks Excluded: not stated Withdrawals: stated Baseline characteristics: no baseline demographic data presented Jadad score: 4
Participants	128 adults: 67M 61F Age range 18‐77 years Inclusion criteria: Asthma as defined by ATS criteria Requirement for inhaled steroids in a dose range of 400‐800 micrograms Exclusion criteria: Cardiovascular disease or diabetes mellitus Baseline asthma control Symptom frequency: not stated FEV1 (% predicted): not stated
Interventions	1. BUD 200 mcg 2xdaily (400 mcg/d) 2.) BUD 400 mcg 2xdaily (800 mcg/d) Delivery device: MDI
Outcomes	FEV1 FVC Morning PEFR Evening PEFR Daily asthma symptom score
Notes	No reply from author to clarify if allocation concealment had been employed. This study was designed as a four period crossover trial. Additional treatment periods with BDP 400 mcg/d and 1000 mcg/d were included: results not considered here.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear